Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration

SHANGHAI, Aug. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced today that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of patients with locally adv...

2026-08-12 08:45 2263

Bracco Marks Major Global Milestone with U.S. FDA 510(k) Clearance and Health Canada Authorization for VueJect®, the First Dedicated Ultrasound Contrast Delivery System to Support Cardiology Imaging

VueJect® strengthens Bracco's integrated CEUS ecosystem by enabling more standardized, efficient contrast administration in cardiology imaging MILAN, Aug. 11, 2026 /PRNewswire/ -- Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to ...

2026-08-11 20:00 1850

Korean Biotech Company K-Medichem Expands Global Market Reach with PDRN Derma Skincare Line in Vietnam, Indonesia and Beyond

* PDRN Derma cream, serum, and mask lineup positions premium K-dermocosmetics based on patented ingredients for Southeast Asian market expansion CHUNCHEON, South Korea, Aug. 11, 2026 /PRNewswire/ -- K-Medichem Co., Ltd. (K-Medichem), a Korean biotech company built on university research, is acc...

2026-08-11 19:17 3000

Korean Biotech Company K-Medichem Expands Global Market Reach with PDRN Derma Skincare Line in Vietnam, Indonesia and Beyond

Cambrex Milan Celebrates 80th Anniversary with Construction of New $30 Million R&D Facility

EAST RUTHERFORD, N.J., Aug. 11, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the start of construction on a new research and development (R&D) facility at its Milan, Italy site. This $30 million investment will add adva...

2026-08-11 18:00 2181

Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates

CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended June 30,...

2026-08-11 17:45 2028

Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery

LAGUNA HILLS, Calif. and SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation f...

2026-08-11 09:30 3281

Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

-ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR. -ASC36 is a potentially first-in-class once-monthly to once-quarterly...

2026-08-10 19:00 3947

Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"

— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements — Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market SEOUL, South Korea, Aug. 10...

2026-08-10 17:36 2787

Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months --

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC), i...

2026-08-10 12:05 2124

Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections

SHANGHAI, Aug. 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspect...

2026-08-10 08:00 2220

RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX e...

2026-08-08 15:46 4225

Alebund's AP301 NDA Accepted for Review by China's NMPA

SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...

2026-08-07 18:40 2827

Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China

NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026,...

2026-08-07 14:44 3614

Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an ...

2026-08-06 19:30 1885

Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per sha...

2026-08-06 18:46 3423

Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment ...

2026-08-06 16:10 2627

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc

2026-08-06 16:00 1374

Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength

HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable de...

2026-08-06 13:17 5308

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2026-08-06 08:00 3859

Telix to Host R&D Day in New York City on September 22, 2026

MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional...

2026-08-06 05:00 2301

1 ... 3 4 567 8 9 ... 346

Week's Top Stories

Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure

[Picked up by 297 media titles]

2026-08-25 10:00

OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth

[Picked up by 291 media titles]

2026-08-24 15:42